Document Detail

In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.
MedLine Citation:
PMID:  21240618     Owner:  NLM     Status:  Publisher    
We aimed to evaluate the efficacy of tocilizumab in patients with rheumatoid arthritis (RA), using the clinical disease activity index (CDAI), and to determine the baseline variables associated with CDAI remission. Fifty-eight patients with active RA were enrolled. We tried to evaluate whether baseline variables were associated with CDAI remission at 24 weeks. Twenty-two of the 58 patients (37.9%) had received tumor necrosis factor (TNF) inhibitors. The continuation rate of tocilizumab at 24 weeks was 87.9%. The seropositivity rates of IgM-rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies at baseline were both 91.4%. The rate of CDAI remission at 24 weeks was 20.7%. We selected baseline variables including age, gender, duration of disease, concomitant use of glucocorticoids, concomitant use of methotrexate (MTX), previous anti-TNF therapy, titer of anti-CCP antibodies (high or low toward median), titer of IgM-RF (high or low toward median), and CDAI, and found that a high titer of IgM-RF was the only variable to be associated with CDAI remission, according to univariate and logistic regression analyses. This is a new finding, and may be specific to tocilizumab as compared with previous observations in anti-TNF therapy.
Shin-Ya Kawashiri; Atsushi Kawakami; Naoki Iwamoto; Keita Fujikawa; Toshiyuki Aramaki; Mami Tamai; Satoshi Yamasaki; Hideki Nakamura; Tomoki Origuchi; Yukitaka Ueki; Kiyoshi Migita; Akinari Mizokami; Kiyoshi Aoyagi; Katsumi Eguchi
Related Documents :
8619398 - Determination of plasma soluble fibrin using a new elisa method in patients with dissem...
7985828 - Plasma levels of tumor necrosis factor and endothelial response in patients with chroni...
11241228 - Acquired bleeding disorder in a patient with malignant lymphoma: antibody-mediated prot...
6403138 - Treatment of haemophilia and related disorders in britain and northern ireland during 1...
9464768 - The presence of hemorrhagic shock increases the rate of bacterial translocation in blun...
10380968 - Alzheimer's disease may not be a spirochetosis.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-1-15
Journal Detail:
Title:  Modern rheumatology / the Japan Rheumatism Association     Volume:  -     ISSN:  1439-7609     ISO Abbreviation:  -     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-1-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100959226     Medline TA:  Mod Rheumatol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Successful treatment of acquired hemophilia A, complicated by chronic GVHD, with tocilizumab.
Next Document:  Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes me...